AMRX Q1 2022 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$498M+0.9% YoY

Gross Profit

$175M35.1% margin

Operating Income

$23M4.7% margin

Net Income

-$2M-0.4% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

-7.3%

Cash Flow

Operating Cash Flow

$76M

Free Cash Flow

$66M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$3.9B

Total Liabilities

$3.5B

Stockholders' Equity

$391M

Cash & Equivalents

$210M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$498M	$493M	+0.9%
Gross Profit	$175M	$192M	-8.9%
Operating Income	$23M	$46M	-49.2%
Net Income	-$2M	$7M	-132.2%

Revenue Segments

Generics Segment

$318M64%

Av K A R E Segment

$95M19%

Amneal Specialty Pharma Segment

$85M17%